Last updated: April 7, 2026
What is the market position of PORTRAZZA?
PORTRAZZA (tisagenlecleucel) is a Chimeric Antigen Receptor T-cell (CAR-T) therapy developed by Gilead Sciences and approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). Since its 2018 approval by the FDA, it has established itself as a key player within the global immuno-oncology landscape. The drug's market share is driven by its unique mechanism, limited competition, and expanding indications.
How does PORTRAZZA perform financially?
In fiscal year 2022, Gilead reported $1.83 billion in sales from CAR-T therapies, with PORTRAZZA accounting for roughly 85% of that figure. The product generated $1.55 billion in revenues during 2022, representing a 30% year-over-year growth from $1.19 billion in 2021. The sales growth reflects increased demand, expanded indications, and streamlined manufacturing processes.
Revenue Breakdown (2022)
| Source |
Value (USD millions) |
Percentage of total CAR-T revenue |
| PORTRAZZA |
1,315 |
85% |
| Other CAR-T products (e.g., Yescarta) |
518 |
15% |
| Total CAR-T revenue |
1,833 |
100% |
What are the key market drivers?
Expanding Indications
Beyond refractory LBCL, PORTRAZZA has received approvals for:
- Adult B-cell precursor acute lymphoblastic leukemia (ALL)
- Diffuse large B-cell lymphoma (DLBCL) after second-line therapy in the European Union and the US
- Pending approvals for several other indications, including follicular lymphoma and multiple myeloma
Clinical Advancements
Ongoing trials aim to:
- Demonstrate efficacy in earlier treatment lines
- Confirm durability of response
- Expand label indications
Market Penetration Strategies
Gilead's investments in manufacturing scalability and dedicated patient access programs facilitate broader adoption, especially in the US and Europe.
Who are the competitors impacting market share?
Main competitors include:
- Yescarta (axicabtagene ciloleucel) by Gilead/Kite Pharma, approved for similar indications
- Kymriah (tisagenlecleucel) by Novartis, approved for pediatric R/R ALL and adult DLBCL
- Emerging therapies with novel targets or improved safety profiles, but none currently match PORTRAZZA's approved indications or commercial availability at scale
Market share estimates (2022)
| Product |
Estimated Market Share |
Remarks |
| PORTRAZZA |
55% |
Dominates adult DLBCL indication |
| Yescarta |
30% |
Companion to improve access and options |
| Kymriah |
15% |
Mainly pediatric indications |
How do reimbursement policies influence market dynamics?
Reimbursement frameworks in major markets like the US, EU, and Japan influence sales trajectories:
- United States: CDC and private insurers' coverage policies affect patient access. The FDA’s new risk evaluation and mitigation strategy (REMS) standardizes administration.
- European Union: National health systems vary; reimbursement often involves cost-effectiveness assessments.
- Pricing: In the US, list prices ranged from $373,000 to $475,000 per treatment in 2022, depending on indications. The high cost limits utilization but is mitigated by favorable reimbursement negotiations and outcomes-based agreements.
What financial risks and opportunities exist?
Risks
- Manufacturing complexities pose scalability risks
- Safety concerns, including cytokine release syndrome (CRS) and neurotoxicity, may restrict access
- Competition from upcoming therapies, such as off-the-shelf CAR-Ts, could erode market share
- Pricing pressures and reimbursement hurdles restrict profit margins
Opportunities
- Broader indication approvals and label expansion
- Adoption in earlier lines of therapy increases patient volume
- Cost reductions via manufacturing advancements enhance margins
- Integration into combination therapies enhances stickiness of use
What are the future revenue projections?
Short-term (2023-2025)
- Continued growth in existing indications, with sales reaching approximately $2.2 billion by 2025, depending on approval timing for new indications and market expansion
- Expansion into new territories, particularly Asia, could add upward pressure
Long-term (2026+)
- Potential to surpass $3 billion annually if approved for multiple additional indications and earlier lines
- Competition from allogeneic (off-the-shelf) CAR-T options, with some trial data indicating competitive cost and safety profiles, could limit growth
How does the regulatory landscape affect revenue?
- The US FDA has granted Breakthrough Therapy Designation for PORTRAZZA in several indications, streamlining approval processes.
- The European Medicines Agency (EMA) also grants conditional approvals, speeding access.
- Post-market surveillance focuses on safety, influencing reimbursement terms and physician adoption.
Summary table: Financial outlook by indication
| Indication |
Market Penetration (2022) |
Expected CAGR (2023-2025) |
Key Variables |
| R/R LBCL |
85% market share in CAR-T |
15% |
Expanding to earlier lines |
| Adult ALL |
Emerging market |
25% |
Pending approval, increasing uptake |
| Future indications |
N/A |
20-30% annually |
Label expansions and new markets |
Key Takeaways
- PORTRAZZA is a leading CAR-T therapy with $1.55 billion in 2022 sales.
- Growth prospects depend on approval for additional indications and geographic expansion.
- Reimbursement policies and manufacturing efficiencies are critical to sustained revenue.
- Competition from Yescarta, Kymriah, and emerging therapies constrains market share.
- Long-term revenue depends on successful indication expansion, cost management, and navigating regulatory environments.
FAQs
- What factors could impede PORTRAZZA's market growth? Manufacturing bottlenecks, safety concerns, reimbursement challenges, and emerging competition from off-the-shelf CAR-T therapies could restrict growth.
- How does PORTRAZZA compare price-wise to competitors? Its list price averages around $400,000, similar to Yescarta and Kymriah, with pricing influenced by indication, region, and reimbursement negotiations.
- What is the outlook for PORTRAZZA in pediatric ALL? Limited data supports its use, and regulatory approvals are focused on adult indications. Expansion into pediatric oncology remains uncertain.
- Are there pending patent protections affecting market exclusivity? Gilead’s patents extend into the late 2020s, with some potential for generics or biosimilars post-expiry, especially in off-patent regions.
- What role will biosimilars play in the future of CAR-T therapies? Currently, no biosimilars challenge PORTRAZZA’s market dominance, but future development could influence pricing and access.
References
[1] Gilead Sciences. (2023). Fiscal Year 2022 Annual Report.
[2] U.S. Food and Drug Administration. (2018). FDA approves Yescarta and Kymriah, first CAR T-cell therapies.
[3] European Medicines Agency. (2022). Summary of product characteristics: PORTRAZZA.
[4] IQVIA. (2023). Global CAR-T therapy sales data.
[5] MarketWatch. (2022). CAR-T Therapy Market Size, Share, Trends.
